MedTrace Logo

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 207

Last updated 2026-02-18

No results posted yet for this study

Summary

The main aim of this study is to check for long-term side effects from ADYNOVI/ADYNOVATE prophylaxis in participants with haemophilia A when used under standard clinical practice in the real-world clinical setting.

Conditions

Interventions

BIOLOGICAL

ADYNOVI/ADYNOVATE

Participants will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national SmPC.

Sponsors & Collaborators

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-09
Primary Completion
2030-02-28
Completion
2030-02-28
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Croatia
  • Czechia
  • Germany
  • Hungary
  • Italy
  • Netherlands
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04158934 on ClinicalTrials.gov